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ABSTRACT
Extracellular vesicles (EVs) are small, heterogeneous and difficult to measure. Flow cytometry (FC)
is a key technology for the measurement of individual particles, but its application to the analysis
of EVs and other submicron particles has presented many challenges and has produced a number
of controversial results, in part due to limitations of instrument detection, lack of robust methods
and ambiguities in how data should be interpreted. These complications are exacerbated by the
field’s lack of a robust reporting framework, and many EV-FC manuscripts include incomplete
descriptions of methods and results, contain artefacts stemming from an insufficient instrument
sensitivity and inappropriate experimental design and lack appropriate calibration and standar-
dization. To address these issues, a working group (WG) of EV-FC researchers from ISEV, ISAC and
ISTH, worked together as an EV-FC WG and developed a consensus framework for the minimum
information that should be provided regarding EV-FC. This framework incorporates the existing
Minimum Information for Studies of EVs (MISEV) guidelines and Minimum Information about a FC
experiment (MIFlowCyt) standard in an EV-FC-specific reporting framework (MIFlowCyt-EV) that
supports reporting of critical information related to sample staining, EV detection and measure-
ment and experimental design in manuscripts that report EV-FC data. MIFlowCyt-EV provides
a structure for sharing EV-FC results, but it does not prescribe specific protocols, as there will
continue to be rapid evolution of instruments and methods for the foreseeable future.
MIFlowCyt-EV accommodates this evolution, while providing information needed to evaluate
and compare different approaches. Because MIFlowCyt-EV will ensure consistency in the manner
of reporting of EV-FC studies, over time we expect that adoption of MIFlowCyt-EV as a standard
for reporting EV- FC studies will improve the ability to quantitatively compare results from
different laboratories and to support the development of new instruments and assays for
improved measurement of EVs.
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Introduction
Extracellular vesicles (EVs) have tremendous potential
value as biomarkers and therapeutic targets [1,2].
However, EVs are small, heterogeneous and therefore
difficult to measure. Sensitive and reproducible methods
for single EV analysis are essential to understand the
biogenesis, diversity and fate of EVs and to apply this
understanding to improve human health. Flow cytometry
(FC) is a powerful method that provides accurate and
precise enumeration of single cells and measurement of
their molecular components. For these reasons there is an
interest in applying FC to the measurement of individual
EVs. However, most commercial flow cytometers, and the
assays that employ them, (i) were designed for the analysis
of cells that are orders of magnitude larger than EVs, (ii)
are not readily adapted to the measurement of EVs and
(iii) generate data which can only be interpreted if all
experimental details are reported. Limitations in instru-
ment sensitivity, assay specificity and a general failure to
adequately report experimental details together have pro-
duced a scientific literature that is rife with artefacts.
General guidelines regarding methods and data
reporting have been developed for both flow cytometry
(Minimum Information about a Flow Cytometry experi-
ment, MIFlowCyt) [3] and EV research (Minimum
Information for the Study of EVs, MISEV) [4,5]. In
addition, the EV-TRACK initiative provides an open
access platform for documenting essential information
for EV publications [6]. However, these resources do
not comprehensively address reporting component
allowing full interpretation of FC data on EVs, which is
critical for the validation and improvement of flow cyto-
metry-based EV analysis. Here, a group of researchers
active in the International Society of Extracellular
Vesicles (ISEV), International Society for Advancement
of Cytometry (ISAC) and/or International Society for
Thrombosis and Haemostasis (ISTH) Vascular Biology
Scientific Standardization Committee, have been working
to develop a framework for reporting EV FC methods
and results, named MIFlowCyt-EV. Consensus about
what to report was reached by discussions spanning sev-
eral years within the WG by teleconferences and by
speaking and presenting ideas to the wider community
satellite meetings at ISEV, ISAC and ISTH conferences.
MIFlowCyt-EV is intended to complement the
MIFlowCyt and MISEV documents by providing
a fundamental reporting structure, with seven cate-
gories, each with clearly defined specific components,
that should be considered and reported for EV FC
studies. MIFlowCyt-EV has been developed to account
for the wide variety of protocols currently used.
MIFlowCyt-EV will be refined and revised periodically,
as EV-related technologies and applications develop, as
is the case for the MIFlowCyt and MISEV guidelines.
MIFlowCyt-EV is structured for researchers to simply
document which of the seven categories and sub-
components were considered, performed and recorded
in the studies. The WG feel that currently there is not
a gold-standard EV flow cytometry workflow, and the
field will continue to struggle to identify robust meth-
ods until EV researchers adopt a standardized frame-
work for reporting data in a consistent, benchmarked
manner.
As well as a reporting framework, MIFlowCyt-EV can
also serve as a guide for the development of educational
resources for researchers desiring to measure EVs. We
expect that this framework will support the development
and validation of new technologies for EV analysis.
MIFlowCyt-EV structure and utilization
MIFlowCyt-EV utilizes the MISEV guidelines from
ISEV for reporting preanalytical variables [4,5], and
the MIFlowCyt guidelines from ISAC for reporting
FC experimental design and general variables related
to FC [3]. The proposed framework for MIFlowCyt-EV
integrates and extends these two established societal
guidelines to promote more standardized reporting of
single EV analyses using FC.
The MIFlowCyt-EV framework addresses seven
areas: 1) preanalytical variables and experimental
design, 2) sample preparation, 3) assay controls, 4)
instrument calibration and data acquisition, 5) EV
characterization, 6) FC data reporting, 7) FC data shar-
ing. Figure 1 shows an overview of the framework and
its components, whereas Table 1 provides a table for
completion of the framework. This framework should
be used for all work where FC is used for the analysis
of single EVs. A template table for the MIFlowCyt-EV
framework can be downloaded from www.evflowcyto
metry.org and is found in Supplementary Table 1. The
component for each category states: “the rationale” for
reporting and “what to report”. Table 2 provides
a “brief example” of the reporting component and is
not intended as “gold standards”. The hypothetical
examples provided for each component are not exhaus-
tive in detail and are not intended to promote the use
of a single particular methodology, but instead to pro-
vide the manner in which each component should be
reported.
Generally, if researchers have performed any of the
components mentioned in this framework, it should be
elaborated upon. However, it is not a requirement to
complete all the framework components. Depending
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upon the design of an experiment, it may be sufficient
to state why completion of a component was not
necessary. It is at the reviewer’s discretion to examine
the completed reporting framework and decide if the
level of detail and utilized controls were sufficiently
conducted and reported.
Preanalytical variables and experimental
design
Pre-analytical factors include the method of sample col-
lection, isolation and storage before measuring. These
preanalytical factors are critical determinants of experi-
mental reproducibility. Isolation steps include proce-
dures to enrich, fractionate and/or concentrate EVs
relative to other sample components. Relevant pre-
analytical factors have been described extensively in the
literature, leading to the development of the MISEV
guidelines, the EV-TRACK platform and other relevant
guidelines from international societies including: ISEV,
ISAC and ISTH [4–9]. We recommend that pre-
analytical variables are reported according to the
MISEV guidelines [4]. Furthermore, we recommend
that the ISAC MIFlowCyt guidelines checklist is com-
pleted and reported for all EV-FC experiments, as well as
to report experimental preanalytical variables related to
basic flow cytometric equipment and reagents [3].
Report preanalytical variables conforming to
MISEV guidelines
Rationale
Preanalytical variables affect the purity and yield of
EVs but vary depending on the sample sources.
Preanalytical variables for clinical samples may include:
needle gauge, collection tube type, sample handling
and EV isolation/enrichment. Furthermore, accounting
for donor-associated variables, such as source, age, sex
or fasting status, may substantially alter biofluid EV
characteristics and therefore the statistical associations
Figure 1. Overview of the MIFlowCyt EV Reporting Framework. The left column shows each category of the reporting framework
and the middle column shows the components within each category, the right-hand column shows the broad objective of each
row. *Highlights the component that are broadly applicable to the majority of single-EV analysis experiments regardless of design or
instrumentation. **Highlights the components that are only applicable in cases where certain reagents or protocols are used.
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of a study. For non-clinical samples, such as tissue
culture-derived samples, pre-analytical variables may
include: culture container, culture medium, incubation
time, growth factors and EV isolation procedures. ISEV
periodically updates the MISEV guidelines to incorpo-
rate consensus on preanalytical variables for a wide
range of sample types and highlights position papers
that detail best-practices for sample collection from
different biological fluids [4,5]. EV-FC experiments
should be reported with information that states what
guidelines or customized procedures were followed.
Report
Preanalytical variables relating to EV sample including
source, collection, isolation, storage and any others
relevant and available in the performed study.
Report experimental design according to
MIFlowCyt guidelines
Rationale
Providing a clear purpose of the performed experi-
ments and a concise and detailed description of the
variables of an FC experiment(s) allows the reader to
understand and interpret the subsequent data of the
performed experiment(s).
Report
EV-FC manuscripts should provide a brief description
of the experimental aim, keywords and variables for the
performed FC experiment(s) using MIFlowCyt check-
list components: 1.1, 1.2 and 1.3, respectively [3].
Completion of the entire MIFlowCyt checklist at this
point is also advised here, in order to address subse-
quent MIFlowCyt checklist components that are inte-
gral to the MIFlowCyt-EV framework components,
such as Components 2.1, 4.1 and 6.1, below.
Sample preparation
The sample preparation components allow for the
reporting of variables that pertain to the sample stain-
ing, washing and dilution for flow cytometric analysis
and do not include preanalytical variables about the
sample listed in Category 1.
Sample staining
Rationale
A number of variables affect the labelling efficacy of
a sample, including: EV concentration, label concentra-
tion, incubation time, temperature, conjugation efficiency,
label-type (and clone if monoclonal antibodies are used)
and light exposure. A particularly critical reporting com-
ponent of these is the final concentration of a label in
appropriate units, for example mole L−1 or µg mL−1.
There are cases where antibody concentration is not pro-
vided or where antibodies are self-conjugated. In these
cases, antibody concentration should be approximated
with a spectrophotometer and the methods reported
appropriately. Self-conjugated antibodies should provide
the conjugation kit catalogue number and lot number.
Report
State any steps relating to the staining of samples. Along
with the method used for staining, provide relevant
reagent descriptions as listed in MIFlowCyt guidelines
(Component 2.4 Fluorescence Reagent(s) Descriptions).
Sample washing
Rationale
Wash steps can affect FC sample measurements by
decreasing the concentration of excess label, thereby
increasing the signal-to-noise ratio. Depending on
how these steps are performed, wash steps may also
dilute or alter the characteristics of the sample being
measured. Reporting details of any wash steps allows
improved reproducibility of FC data.
Table 1. MIFlowCyt-EV framework.
Framework components
Complete for each
component
1.1 Preanalytical variables conforming to MISEV
guidelines*
1.2 Experimental design according to
MIFlowCyt guidelines*
2.1 Sample staining details*
2.2 Sample washing details*
2.3 Sample dilution details*
3.1 Buffer-only controls*
3.2 Buffer with reagent controls*
3.3 Unstained controls*
3.4 Isotype controls**
3.5 Single-stained controls*
3.6 Procedural controls**
3.7 Serial dilutions*
3.8 Detergent-treated controls
4.1 Trigger channel(s) and threshold(s)*
4.2 Flow rate/volumetric quantification*
4.3 Fluorescence calibration*
4.4 Scatter calibration
5.1 EV diameter/surface area/volume
approximation
5.2 EV refractive index approximation
5.3 EV epitope number approximation
6.1 Completion of MIFlowCyt checklist*
6.2 Calibrated channel detection range
6.3 EV number/concentration
6.4 EV brightness
7.1 Sharing of data to a public repository
*Highlights the components that are broadly applicable to the majority of
single-EV analysis experiments regardless of design or instrumentation.
**Highlights the components that are only applicable in cases where
certain reagents or protocols are used.
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Table 2. Example of a completed MIFlowCyt-EV framework.
Component Brief example
1.1 Blood was collected from 100 individuals in 5 mL 0.109 M citrated plastic tubes (BD Vacutainer, Becton Dickinson) via antecubital vein
puncture using a 21-gauge needle. The first 1 mL was discarded, prior to collection of 3.5 mL of blood. Tubes were transported vertically
at room temperature. Within 1 hour of blood withdrawal, platelet-depleted plasma was prepared by centrifugation (Eppendorf 5810-R
centrifuge, S-4-101 Rotor, Eppendorf) twice at 2500 ×g for 15 minutes at 20 °C. The lowest deceleration setting was used, setting ‘1ʹ. The
first centrifugation step was done with 3.5 mL whole blood in 5 mL tubes (BD Vacutainer, Becton Dickinson). Supernatant was collected
10 mm above the buffy coat. The second centrifugation step was done with 2.5 mL platelet-depleted plasma in 15 mL conical tubes
(Falcon Conical, Corning). The absence of haemolysis is confirmed by the lack of a spectrophotometric absorbance peak of free
haemoglobin at 414 nm using a BioDrop DUO spectrophotometer. 1 mL x2 aliquots of platelet-depleted plasma were transferred to
1.5 mL low-protein binding Eppendorf tubes (Thermo Fisher Scientific) and snap frozen in liquid nitrogen before being stored at −80 °C.
Age, sex, fasting status and smoking status were recorded for all individuals.
1.2 1.1 Aim: To compare the concentration of CD41a+ platelet-derived EVs in platelet-depleted plasma between individuals with type-2
diabetes mellitus (T2DM) and healthy controls. We hypothesize that the concentration of platelet-derived EVs will be increased in
individuals with T2DM as T2DM has been associated with increased platelet activation. 1.2 Keywords: EV; extracellular vesicles, T2DM;
type-2 diabetes mellitus. 1.3 Experimental variables: Platelet-depleted plasma samples were measured from 50 individuals with T2DM
and 50 healthy controls. There was no significant difference in age, sex, fasting-status or smoking-status between individuals with and
without T2DM. Scatter-based triggering was used for the detection of particles.
2.1 The presence of CD41a was determined using CD41a antibody staining. Please see Table 2 for an overview of the reagents used. 5 × 109 EVs
(estimated by resistive pulse sensing (nCS1, Spectradyne) after size-exclusion chromatography (SEC) treatment) suspended in 495 µL of
Dulbecco’s phosphate-buffered saline (DPBS) were incubated with 1x vFRed membrane stain (Cellarcus Biosciences), 5 mM CaCl2 (Sigma
Aldrich), 20 µM PPACK (Sigma Aldrich), and 5 µL of 25 µg mL−1 anti-human CD41a mouse-IgG1κ-PE (BioLegend) for one hour at 20°C and
protected from light. A matched isotype control, mouse-IgG1κ-PE (BioLegend), was incubated in the same conditions and concentration
(0.25 µg mL−1) as the anti-CD41a stained sample. The final concentration used for EV measurement using serial dilution 5 was
(0.016 µg mL−1) for anti-CD41a and its matched isotype.
2.2 Unbound antibody from CD41a-stained EV samples was removed using SEC. 500 µL of sample was added to a size exclusion column and
performed according to manufacturer recommendations. Briefly, the column (qEV Original, Izon Science) was next eluted with
0.2 µm-filtered DPBS and 500 µL fractions were collected. Fractions 7–9 were subsequently pooled together for analysis. The column flow
rate was ~0.8–1.2 µL min−1, with 500 µL DPBS buffer manually maintained on top of the column.
2.3 30 µL of platelet-depleted plasma was added to 5 µL of reagents and 265 µL of DPBS, resulting in a 10-fold dilution. This 10-fold dilution
was then serially diluted six times, with 150 µL of sample added to 150 µL of DBPS in a 96-well polypropylene plate (Corning). All wells
were measured with the fifth serial dilution (320-fold dilution) in the series used for calculating EV concentration in the starting material.
3.1 A buffer-only control of 0.1 µm-filtered DPBS was recorded at the same flow cytometer acquisition settings as all other samples, including
triggering threshold, voltages, and flow rate. The buffer-only control had a count of ~100 events s−1.
3.2 A buffer with reagent control (0.25 µg mL-1 anti-human CD41a mouse-IgG1κ-PE (Clone: HIP8, Manufacturer: BioLegend, Cat No. 303,706, Lot
No. B250952) was recorded at the same flow cytometer acquisition settings as all other samples, including triggering threshold, voltages,
and flow rate. This control was serially diluted 6 times, with 150 µL of buffer with reagent added to 150 µL of DBPS to allow comparisons
between serially diluted stained samples. Buffer with reagent controls had an event rate of ~100 events s−1 and were therefore not
changed from the buffer-only control.
3.3 Unstained controls were measured at the same dilution as matched stained and isotype controls. Flow cytometer acquisition settings were
maintained for all samples, including triggering threshold, voltages, and flow rate. The event rate of unstained controls differed by <5%
from isotype controls. No substantial changes in scatter or fluorescence signals were observed between unstained and matched isotype
controls.
3.4 Isotype controls were used at the same concentration as matched stained controls and were recorded at the same dilution as matched
stained and unstained controls and stained samples. Please see Table 3 for further reagent information. Flow cytometer acquisition
settings were maintained for all samples, including triggering threshold, voltages and flow rate. No substantial changes in scatter or
fluorescence signals were observed between unstained and matched isotype controls.
3.5 vFRed (Cellarcus Biosciences) and anti-human CD41a mouse-IgG1κ-PE (BioLegend) single-stained controls for a reference set of samples
were analysed to aid compensation of anti-human CD41a mouse-IgG1κ-PE into the vFRed channel when excited by the 488 nm laser.
3.6 Excess antibody was reduced by further purification of the stained EVs using SEC columns (qEV Original, Izon Science), with fractions 7–9
collected for analysis. To assess whether this step caused artefacts, 500 µL of each control sample (buffer alone, buffer with reagent,
unstained, and isotype controls) was run through a SEC column with 500 µL fractions (7–9) collected for analysis. These SEC processed
samples were compared to a sample of unprocessed buffer alone, buffer with reagent, unstained sample, isotype sample, and stained
sample to demonstrate the removal of antibody with no artefacts being introduced from the procedure.
3.7 Samples were serially diluted six times, with 150 µL of sample added to 150 µL of DBPS and measured using a 96-well polypropylene plate
(Corning). The 4th, 5th and 6th dilutions showed a linear decrease between dilution factor and measured particle count over one minute.
The median fluorescence and scatter intensity of all events for dilutions 4, 5 and 6 were maintained at 500 ± 18 PE molecules of
equivalent soluble fluorophore (MESF; See Component 4.3 for MESF calibration), and 3000 ± 31 side scatter arbitrary units, respectively.
Dilutions 1–3 did not show a linear correlation between dilution factor and measured event count, nor were their fluorescence and scatter
intensity maintained. The fifth serial dilution (320-fold dilution) in the series was therefore used to calculate EV concentration and report
immunostaining data.
3.8 Stained samples, diluted 320-fold, were treated with 0.1% Triton X-100 for 5 min at 21°C to test the lability of vFRed and CD41a-PE stained
events. These measurements were used to compare vFRed and CD41a-PE stained samples not treated with detergent. vFRed and CD41a-
PE positive events decreased 87% ± 9% upon treatment with 0.1% Triton X-100 for 5 min.
4.1 Based on the buffer alone control (Component 3.1), detection was triggered on the 488 nm laser excited PE-Texas Red channel (630/30
bandpass filter) at a threshold of 500 arbitrary units, equivalent to ~50 PE-Texas Red MESF, determined using Spherotech Rainbow beads
and the manufacturer’s calibration values (see Component 4.3 flor fluorescence calibration). The buffer alone control (Component 3.1)
had an event rate of ~100 events s−1.
4.2 Samples were enumerated using the integral instrument flow rate sensors, resulting in a flow rate of 10 µL min−1. This was calibrated using
weighed volumes of deionized water prior to analysis.
4.3 Arbitrary PE fluorescence scale units (channel number), excited by the 561 nm laser and collected using a 586/15 bandpass filter, were
converted to MESF units using PE Quantibrite beads (Becton Dickinson, Cat. 100,001, Lot. L1000001). Least-squares regression was
performed between log10-transformed values of PE-A intensities versus bead PE MESF units (provided by manufacturer) using the 3
dimmest bead populations. The resulting regression showed a high correlation with an R2 value of 0.99, with a slope of 0.931 and
intercept of 1.345.
(Continued )
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Report
State any steps relating to the washing of samples.
Sample dilution
Rationale
The concentration of EVs in the starting material
(body fluid, culture media) is a highly reported statistic
from EV-FC data but is affected by sample dilution.
Sample dilution can occur from the addition of buffers,
reagents and wash steps. Accounting for all dilution
steps that occurred from sample collection to analysis
is therefore crucial.
Report
All methods and steps relating to sample dilution.
Assay controls
Due to the unique challenges of EV-FC several controls
may be required that are typically not used when
analysing cells or other micron-sized particles. We
recommend reporting whether the following controls
have been included in an experiment: buffer alone,
buffer with added reagents but without EVs, proce-
dural controls, detergent-treatment of samples and
demonstration of single particle detection.
Buffer-only
Rationale
Flow cytometer background noise depends on several
factors across the instrument’s optics, electronics and
fluidics. The acquisition of a buffer-only control provides
a measure of the instrument’s background event rate at
the same settings used to analyse EV samples and further
controls [10]. Flow cytometers tend to use water or buf-
fered saline solution as sheath buffer. Differences between
sample solution and sheath buffer can contribute to back-
ground in flow cytometric analysis [11]. The effects of
sample solution on background signals are well known in
cellular FC, for example analysis of cells in media solution
containing phenol red, can contribute to elevated fluores-
cence and may interfere with the analysis of “staining”
Table 2. (Continued).
Component Brief example
4.4 Side scatter calibration was performed using Mie modelling software, taking into account the wavelength (405 nm) and polarization state
(perpendicular to detection) of the laser, the light collection geometry (side scatter, numerical aperture 1.2), and the particle diameter and
refractive index. Least square fitting was used to relate the median signal of each National Institute of Standards and Technology (NIST)-
traceable polystyrene bead population to the theory, resulting in a linear scaling factor of 11.3 and an R2 of 0.99. The limiting side scatter
collection angle range of the instrument was determined to be 38-142°, based on the flow cell dimensions. Scatter calibration was shown
by plotting modelled vs acquired polystyrene bead data.
5.1 EV diameter was approximated using the fluorescence intensity of a membrane intercalating dye; vFRed. The vFRed cytometer collection
channel was calibrated using vFRed-stained liposomes of known population diameter (median 100 nm, range ~50–150 nm) and surface
area distributions, determined using nanoparticle tracking analysis (NTA) and resistive pulse sensing (RPS). To calibrate flow cytometer
fluorescence intensity in terms of equivalent surface area, a least-squares linear regression was performed between the liposome
population surface area and vFRed fluorescence intensity distributions.
5.2 Particle refractive index was derived from the ratio of side and forward scatter signal (i.e. Flow-SR). NIST traceable polystyrene beads with
known size and refractive index (Exometry, Netherlands) were used to create a mathematical model of the optical configuration of the
flow cytometer using FCMPASS software. Using this model, a Flow-SR versus diameter lookup table was calculated, which allows
determination of the particle diameter from the measured Flow-SR. The determined diameter was subsequently used to derive the
refractive index from a lookup table of side scatter versus diameter. Lookup tables were calculated for diameters ranging from 10 to
1000 nm, with step sizes of 1 nm, and refractive indices from 1.35 to 1.80 with step sizes of 0.001.
5.3 Anti-mouse antibody capture beads (ABC) (Quantum simply cellular, Bangs Laboratories, Cat No. 100,001, Lot No. L1000001) were incubated
with 5 µL of 25 µg mL−1 anti-CD41a mouse-IgG1κ-PE (Clone: HIP8, Manufacturer: BioLegend, Cat No. 303,706, Lot No. B250952) for 15 min
at 20°C and protected from light. The PE channel units were converted to ABC units by performing regression between PE-A and ABC
number using the 3 dimmest bead populations. Regression showed a high correlation with an R2 value of 0.99.
6.1 The MIFlowCyt checklist v1.0.0 has been completed and attached in the Supplementary Information.
6.2 The median intensity of the unstained EV population was 200 PE MESF units. The maximum channel number (218), when scaled to MESF,
was 592,435 PE MESF units. Positive events on PE were assumed to be two standard deviations above the unstained EV population, 240
PE MESF units. The detection range of the PE channel used for PE-positive events was therefore 320 to 592,435 PE MESF units.
6.3 The detected concentration of CD41a-PE positive EVs between calibrated detection range (240 and 592,435 PE MESF units) was 5.62 × 108
particle mL-1. Flow cytometer acquisition settings were maintained for all samples, including triggering threshold, voltages and flow rate.
6.4 EV brightness was compared using the median (25th, 75th percentile) PE MESF intensity, due to the non-parametric distribution of EV
staining. Unstained platelet-derived EVs from healthy patients and T2DM patients had a median fluorescence intensity of 240 (290, 120)
PE MESF. CD41a-positive platelet-derived EVs from healthy patients had a median fluorescence intensity of 535 (800, 205) PE MESF units.
CD41a-positive platelet-derived EVs from T2DM patients had a median fluorescence intensity of 560 (890, 250) PE MESF units.
7.1 FC files and the analysis workspace have been uploaded FlowRepository and can also be obtained by contacting the corresponding author.
This example is of a hypothetical experiment. The WG does not currently believe there exists a “gold-standard” methodology or endorse any particular
purification methods, reagents, assays or equipment. At the time of publication, no literature exists on the described hypothetical experiment. This
hypothetical experiment was designed purely to require that every component of the framework be utilized and need a moderate level of detail. In many
assays, every component of the framework may not need to be completed in detail if it is not relevant to the assay. In the case of a component not be
relevant to an assay, a brief explanation as to why any specific component was not required should be reported. This completed example is purely
a reference to the type of details that are relevant for each component and to the extent they should be discussed.
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with a fluorophore that has spectral overlap. When ana-
lysing small particles at the limits of a flow cytometer’s
sensitivity, it is important to provide a reference of the
recorded event rate from a sample which contains only
the buffer used for diluting EV-containing samples.
Report
State whether a buffer-only control was analysed at the
same settings and during the same experiment as the
samples of interest. If utilized it is recommended that
all samples be recorded for a consistent set period of
time, for example 5 min, rather than stopping analysis
at a set recorded event count, for example 100,000
events. This allows comparisons of total particle counts
between controls and samples.
Buffer with reagents
Rationale
To demonstrate if the background signal is altered, for
example buffer with reagent control shows events that
appear positive for fluorescence and light scatter in the
absence of EV-containing samples. This control is a direct
comparison to the buffer-only control (Component 3.1).
The appearance or change of a population allows the
identification of reagent-related effects that could affect
the analysis of EV-stained samples [12]. When unbound
labels or aggregates of labels are not removed, some
instruments are able to detect the signal of these mole-
cules which may be artifactually interpreted as EVs
[10,13–15].
Report
State whether a buffer with reagent control was ana-
lysed at the same settings, same concentrations and
during the same experiment as the samples of interest.
If used state what the results were.
Unstained controls
Rationale
Unstained controls provide an estimate of the background
events and/or signal that may be expected with isotype
and/or stained samples. These controls are a useful tool to
compare between other samples and controls for the
event rate, signal intensity and gating strategies.
Report: State whether unstained control samples
were analysed at the same settings and during the
same experiment as stained samples. If used, state
what the results were, preferably in standard units.Ta
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Isotype controls
Rationale
The effect of isotype controls compared to unstained
controls and stained samples can provide a useful
method of identifying confounding effects related to
antibody specificity. Along with the buffer with reagent
control and procedural controls, isotype controls may
also helpful to identify false-positive expression of mar-
kers due to the presence of high-amounts of unbound
antibodies [16].
Report
The use of isotype controls is applicable to immuno-
fluorescence labelling only. State whether isotype con-
trols were analysed at the same settings and during the
same experiment as stained samples. If utilized, state
which antibody they are matched to, the concentration
used and what the results were (Component 4.2, 4.3,
4.4). Due to conjugation differences between manufac-
turers if should be stated if the isotype controls are
from the same manufacturer as the matched
antibodies.
Single-stained controls
Rationale
FC experiments often use multiple fluorescent reagents.
Therefore, it is important to be able to assess whether
a fluorescent reagent’s spectrum is affecting the mea-
surements in the detection parameter of another fluor-
escent reagent. Single stained controls may also be
useful for compensation, validating compensation by
other means such as compensation beads, or identify-
ing potential confounding factors from staining, for
example fluorescence quenching.
Report
State whether single-stained controls were included. If
used state whether the single-stained controls were
recorded using the same settings, dilutions and during
the same experiment as stained samples and state what
the results were, preferably in standard units
(Component 4.2, 4.3, 4.4).
Procedural controls
Rationale
Some staining methods require further purification/
processing after labelling of EVs to remove excess dye
[10,14,15,17]. In these cases, including procedural con-
trols can show that no artefacts were introduced into
the sample during post-staining processing. Procedural
controls would include the same buffer-only and buffer
with reagent(s) controls (Component 3.1 and
Component 3.2) but prepared according to the proce-
dure used to further purify/process the stained samples.
These controls can then be compared to controls from
Component 3.1 and Component 3.2 to show that the
further purification/processing steps did not produce
artefacts. Examples of post-staining purification/pro-
cessing method that may require procedural controls
include ultracentrifugation, density gradient flotation,
(ultra)filtration and size-exclusion chromatogra-
phy (SEC).
Report
State whether procedural controls were included. If
used, state the procedure and if the procedural controls
were acquired at the same settings and during the same
experiment as stained samples.
Serial dilution
Rationale
Serial sample dilution can assist with the evaluation of
whether EVs are being detected as single particles.
This is to avoid coincidence detection, also known
as “swarm detection”, whereby multiple particles are
present in the illuminated region of the core stream
and their combined light scatter and fluorescence
signals are merged into a single event [18]. Serial
dilutions can also determine whether confounding
factors such as background particles and unbound
dyes/antibodies are affecting scatter or fluorescence
signals. Serially diluting samples whilst maintaining
a consistent fluorescence and/or scatter signal inten-
sity and maintaining a linear particle count consistent
with the dilution factor, have been used to in litera-
ture to statistically demonstrate the detection of sin-
gle-particles of interest [10,16,19–22]. Further gating
strategies can also be applied to avoid coincidence
detection.
Report
State whether serial dilutions were performed on sam-
ples and note the dilution range and manner of testing.
The fluorescence and/or scatter signal intensity would
ideally be reported in standard units (see Component
4.3, 4.4) but arbitrary units can also be used. These
data are best reported by plotting the recorded number
events/concentration over a set period of time at dif-
ferent sample dilution. The median fluorescence inten-
sity at each of the dilutions should also ideally be
plotted on the same or a separate plot. An example is
shown in Figure 3(a).
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Detergent-treated EV samples
Rationale
Detergent controls aid in determining whether detected
events are membrane-enclosed vesicles or other protein
complexes. Complexes can be present when measuring
heterogeneous samples such as plasma and serum, or
when using reagents are used that may cause precipita-
tion, such as calcium phosphate. Detergent-treatment
will lyse membrane-enclosed vesicles, reducing their
number and signals. Detergent resistant particles,
such as protein complexes or other particulates, will
persist following detergent lysis, thereby allowing dif-
ferentiation from EVs [20,23–25].
Report
State whether samples were detergent treated to assess
lability. If utilized, state what detergent was used, the
end concentration of the detergent and what the results
were of the lysis.
Instrument calibration and data acquisition
Flow cytometers have numerous operating parameters
that will affect the measured events. Completing the
MiFlowCyt checklist in Component 1.2 of this report-
ing framework covers the reporting of many of these
parameters. However, some flow cytometer parameters
are conventionally set and reported in arbitrary units.
To support the comparison and validation of data
between experiments, instruments, laboratories and
institutions, this section provides the components and
rationale for reporting the settings and readouts of flow
cytometers in standard units. Here, calibration refers to
the conversion of arbitrary units into standard units.
This relies upon interpolation and extrapolation of
signals from reference particles, as summarized and
referenced below. This is distinctly different from
instrument configuration whereby beads may be ana-
lysed to find optimal detection settings.
Trigger channel(s) and threshold(s)
Rationale
Instrument trigger and threshold parameters are criti-
cal in defining the instrument is and is not able to
detect, and therefore the data collected for analysis.
For EV-FC experiments to be reproduced, similar trig-
ger and threshold settings are required, and for differ-
ent investigators to reproduce these settings on
different instruments, it is necessary for the settings
to be able to be approximated based on standardized
metrics. The reporting of trigger(s) and/or threshold(s)
is an integral element of the MIFlowCyt reporting
guidelines for all FC experiments.
Report
The trigger channel(s) and threshold(s) used for event
detection. Preferably, the fluorescence calibration
(Component 4.3) and/or scatter calibration
(Component 4.4) should be used in order to report
the trigger channel(s) and threshold(s) in standardized
units.
Flow rate/volumetric quantification
Rationale
Calculation of the EV concentration requires a known
flow rate. However, because the adjusted flow rate may
deviate from the actual flow rate, it is good practice to
measure the flow rate periodically. Methods for flow
rate determination depend on the flow cytometer.
There are various methods for monitoring flow rate,
including counting beads, weighing samples before and
after acquisition and integral instrument flow rate sen-
sors [26,27].
Report
State if the flow rate was quantified/validated and if so,
report the result and how they were obtained.
Fluorescence calibration
Rationale
Flow cytometers differ in their fluorescence sensitivity
and dynamic range. A number of factors can lead to
changes to an instruments sensitivity and dynamic
range over time and therefore results in differences
between experiments. Due to differences between instru-
ment sensitivities, EVs may be identified as positive on
one instrument, but appear negative on another instru-
ment. In order to accurately compare data between flow
cytometers, whose axes are in arbitrary units,
a calibration must be performed to convert data from
arbitrary to standard measurement units. Calibrating
fluorescence scales from arbitrary units into standardized
units for reporting provides improved comparisons of
results between different experimental protocols and
instruments with different sensitivities and differing
experimental protocols [10,16,25,28]. Fluorescence cali-
bration is relatively simple to perform with protocols and
reagents available from multiple manufacturers and most
commercially available cytometry software capable of
performing it. Put simply, the known fluorescent values
of each bead population are plotted against their arbi-
trary unit intensity and a regression line is drawn
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through these points. The slope and intercept of the
regression line are then used to convert the arbitrary
values to a calibrated scale. A number of common fluor-
ophores are available with molecules of equivalent solu-
ble fluorophore (MESF) beads. In the absence of MESF
bead availability for a specific fluorophore, it is possible
to use beads with a known binding capacity for IgG
(antibody bound per cell (ABC) beads) which capture
the conjugated antibody being used standardized in the
assay. In cases where it is not possible to use MESF or
ABC beads (such as membrane dyes), equivalent refer-
ence fluorophore (ERF) beads can be used. These beads
have a broad emission spectrum and can standardize
work on cytometers using the same filter sets. However,
ERF beads are less accurate than MESF or ABC beads
but are a useful method to approximate fluorescent mea-
surements in a standard manner.
Report
State whether fluorescence calibration was implemen-
ted, and if so, report the materials and methods used,
catalogue numbers, lot numbers and supplied reference
units for the standards. Fluorescence parameters may
be reported in standardized units of MESF, ERF or
ABC beads. The type of regression used and the result-
ing scatter plot of arbitrary data versus standard data
for the reference particles should be supplied. An
example plot is shown in Figure 3(b).
Light scatter calibration
Rationale
Light scatter signals are complex to standardize across
different FC platforms. This is because the amount of
light scatter detected from any given particle is depen-
dent on a number of variables, including its diameter, its
composition and refractive index, the refractive index of
the suspension medium and the range of angles and
geometry of light collected by a FC platform [18]. Due
to these differences, the use of polystyrene beads alone
does not result in a calibrated scatter detector, nor can it
be used to compare instrument resolution and sensitivity
for particles other than polystyrene beads. Thus, a gating
strategy based on polystyrene beads alone is not a sound
standardization methodology [18,29]. The calibration of
any scattering channel (FSC, SSC, MALS, etc.) from
arbitrary units to standard units requires the use of Mie
modelling software [18,22,30–32]. Light scatter calibra-
tion provides information that is essential for any cross-
platform interpretation and will allow reproducibility of
EV measurements performed on instruments with dif-
ferent optical configurations and settings. The use of
modelling also provides a method of displaying
instrument light scatter sensitivity independently or
refractive index (Figure 3(c)) [18,22,31,32].
Report
State whether and how light scatter calibration was
implemented. Light scatter parameters may be reported
in standardized units of nm2, along with information
required to reproduce the model.
EV characterization
A number of EV characteristics can potentially be
inferred from FC data, including diameter, refractive
index and number of epitopes. Understanding the deri-
vation of EV characteristics requires expertise as well as
specific controls. Currently, the majority of the EV-FC-
WG, as referees, would not expect these characteriza-
tions to be performed in all or most manuscripts
(Figure 2). If performed, however, these advanced deri-
vations should be reported as follows.
EV diameter/surface area/volume approximation
Rationale
The determination of EV diameter provides a method
of normalizing data between experiments and having
a quantification of instrument sensitivity. This has been
demonstrated using Mie modelling of one scatter
detector, by calibrating the ratio between side and
forward scatter and by surface area approximation
using fluorescence [24,25,30,31,33].
Report
State whether and how EV diameter, surface area and/
or volume have been calculated using FC
measurements.
EV refractive index approximation
Rationale
The determination of refractive index may indicate
differences in EV composition (protein vs. lipid levels,
cargo) or allow a method for defining gates for EV
analysis or exclusion of events from analysis.
Refractive index approximation using data from FC
instruments has been demonstrated for EVs larger
than 200 nm using the flow cytometry scatter-ratio
(Flow-SR) methodology (Figure 3(d)) [33] and multi-
angle scattering detection [34].
Report
State whether the EV refractive index has been
approximated and how this was done.
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EV epitope number approximation
Rationale
EV epitope number may provide an insightful method
of normalizing data between experiments. This differs
from EV brightness in MESF/ERF/ABC units as it must
account for further variables such as antibody valency,
avidity, clone and conjugation [35,36].
Report
State whether EV epitope number has been approxi-
mated, and if so, how it was approximated.
FC data reporting
Most EV-FC experiments are performed to determine what
markers can be detected on individual EVs and what the
concentration of those EVs is in a sample. In order to ensure
that these measurements can be reproduced across labora-
tories that are using different instruments with different
configurations and settings, it is important that the data
from these experiments are presented in a way that is
standardized. These standardized measurements will, in
turn, help the research community compare available cyt-
ometers and protocols for EV analysis.
Complete MIFlowCyt checklist
Rationale
The MIFlowCyt checklist was developed in order to pro-
vide a standardized method of reporting experimental
and flow cytometer parameter pertinent to the experi-
ment interpretation and reproducibility. These include
the reporting of instrument settings such as laser power,
detector settings and filter sets. It should be noted that
many instrument settings are automatically saved to the “.
fcs” -files that are generated by flow cytometers. FC soft-
ware analysis packages also have built-in functions to
record MIFlowCyt checklist parameters to the experi-
ment workspace, which in turn can also be uploaded to
public repositories such as FlowRepository. When
uploaded to public repositories such as FlowRepository
which read each “.fcs”-file, instrument settings are also
imported and are therefore easily accessible [3,37].
Report
Complete MIFlowCyt checklist components 1 to 4
using the MIFlowCyt guidelines.
Figure 2. Summary of a poll about what extracellular vesicles (EV) flow cytometry (FCM) working group (WG) members expect to be
reported in scientific manuscripts on EV-FC. The top chart shows the number of working group members who have experience
reviewing manuscripts from the ISEV, ISAC, ISTH journals (red) and those that have not (white). The bottom bar graph summarizes
the personal expectations of all co-authors regarding components to be reported in EV-FC manuscript published in ISEV, ISAC and
ISTH journals. The expectations fall into categories of all (blue), most (green) or select/specialized (yellow) manuscripts.
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Calibrated channel detection range
Rationale
Flow cytometers have a limited dynamic range and are
therefore only capable of detecting signals between
a set range. Stating the lower and upper limited of
the detection channel range is a method of normalizing
data between instruments with different sensitivity
limits.
Figure 3. (a) Example plot of reporting serial dilutions data, with event count per second on the left y-axis, median PE MESF
intensity of the recorded data on the right y-axis and the dilution factor on the x-axis. (b) Example plot of reporting fluorescence
calibration using regression. The fluorescent intensity in arbitrary units (channel number) is on the x-axis with the related
fluorescence population reference units on the y-axis. (c) Example plot of light scatter calibration at 405 nm using FCMPASS software
default values. (d) Example plot of refractive index and diameter determination using Flow-SR. methodology.
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Report
If fluorescence or scatter calibration has been carried
out, authors should state whether the upper and lower
limits of a calibrated detection channel were calculated
in standardized units. This can be done by converting
the arbitrary unit scale to a calibrated scaled, as dis-
cussed in Component 4.3 and 4.4, and providing the
highest unit on this scale and the lowest detectable unit
above the unstained population. The lowest unit at
which a population is deemed “positive” can be deter-
mined a variety of ways, including reporting the 99th
percentile measurement unit of the unstained popula-
tion for fluorescence. The chosen method for deter-
mining at what unit an event was deemed positive
should be clearly outlined.
EV number concentration
Rationale
Due to flow cytometers having a varying sensitivity and
a limited detection range (Component 6.2), only
a portion of the full EV population may be detected.
Reporting concentration as a number of detected EVs
between a calibrated detection range enables standar-
dized reporting and makes data reproducibility and
validation possible. This detection range can take the
form of MESF units, scattering units (nm2), diameter,
or others [38]. Due to cytometers being unable to
differentiate between very dim and negative popula-
tions percentages should not be used to quantify EVs
using immunophenotyping.
Report
State whether EV number/concentration has been
reported. If calculated, it is preferable to report EV num-
ber/concentration in a standardized manner, stating the
number/concentration between a set detection range.
EV brightness
Rationale
Using calibrated units to report the fluorescence and/or
scatter signals as statistical summaries, histograms, or
scatter plots, provides a standardized reporting method
that makes data reproducibility and validation possible.
Report
When applicable, state the method by which the
brightness of EVs is reported in standardized units of
scatter and/or fluorescence.
FC data sharing
Scientific publications have limited space for extensive
figures and both journals and scientists tend not to
publish many control data points. It is however impor-
tant as a reader or reviewer to be able to inspect the
quality of data acquisition and particularly the experi-
mental controls (described in Category 3), when inter-
preting a piece of published work.
Share data to public repository
Rationale
Public access to published data allows other researchers
to inspect control and acquired sample data. Public access
to data has been found to improve the reporting accuracy
in manuscripts and provides important transparency for
referees and readers of published work. For these reasons
many funding agencies require public release of data. All
human subject’s data with Personally Identifying
Information (PII) must be deidentified prior to collection
or data deposition. FlowRepository was developed in
tandem with the MIFlowCyt guidelines as a public data
repository to support open access of data from published
and unpublished work and aids the completion of the
MIFlowCyt components (Component 1.2, Component
6.1) by archiving data from the FC “.fcs”-files [37]. Data
repositories tailored to EV-FC data are yet to be devel-
oped, but standard format (FC) data may be deposited at
a number of data repositories (FlowRepository, Immport,
Mendeley, Zenodo, figshare, etc.).
Report
Provide a link to the experimental data in a public data
repository.
Broadly applicable experimental components
of MIFlowCyt-EV
While this work aims to outline a standard reporting
framework rather than set guidelines, it is clear that
some components of the MIFlowCyt-EV framework
are important to utilized and reported in the majority
of single-EV analysis experiments regardless of design
or instrumentation. These include components 1.1, 1.2,
2.1, 2.2, 2.3, 3.1, 3.2, 3.3, 3.5, 3.7, 4.1, 4.2, 4.3 and 6.1, as
highlighted in Table 1 and Figure 1. The use of com-
ponents 3.4 and 3.6 should also be seen as a necessity
should antibody staining, or post-stain wash methods
be utilized, respectively. While the other components
are still applicable, the other framework components
have different degrees of importance, depending on the
experimental objectives and design and on the scope of
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claims that are based on the reported EV FC results.
For example, Component 5.1 is not relevant if work
does not describe the detection limit of an instrument
using diameter related claims. However, if a piece of
work does make conclusions about the limit of an
instrument detection using size-related claims,
Component 5.1 should be addressed.
Discussion
In the course of attempting to execute two sequential
ISEV-ISAC-ISTH EV FCM WG Standardization
Studies, with standards and samples distributed to
12–18 WG laboratories worldwide, we found that,
even among EV FC groups that are at the forefront of
the EV FC research field, we were not able to define
a consensus guidelines for the best methods, instru-
ments, controls and analytical tools to use for a simple
set of reference samples. However, the WG did arrive
at a consensus regarding what information would assist
with the interpretation and reproducibility of results
across different platforms, sample types and methods.
This consensus is reflected in the MIFlowCyt-EV
Framework for reporting EV FC studies.
The MIFlowCyt-EV framework stems from several
years of collaborative work by an international group
of researchers working together in the ISEV-ISAC-
ISTH EV-FC WG. While an implied goal of these
efforts is the comparison of methods and technologies
for EV measurement, it quickly became clear that more
complete and uniform reporting of assay methods and
results would be required for this to be possible, since
most members employ a diverse range of instruments
and assay designs to measure a common set of repre-
sentative EV samples. However, the ISEV-ISAC-ISTH
EV-FC-WG also realized the importance of developing
such a framework by consensus. Presentations, discus-
sions and workshops taking place at the ISEV, ISAC
and ISTH annual conferences have been fundamental
to its development.
A poll of the active participants of the EV-FC-WG
provided insight into the level of current consensus on
the necessity of reporting/carrying out each of the frame-
work components regardless of the EV-FC experiment
being reported. This poll was not a reflection of the frame-
work itself, as it was fully agreed upon by all members of
the WG. The poll was instead a method to stratify the
current experimental expectations of the field which was
not addressed in this work. The group voted unanimously
that preanalytical variables and experimental design
(Category 1) should be reported in all or most manu-
scripts. More than 95% of the group voted that sample
preparation steps (Category 2) should be reported in all or
most manuscripts. The reporting of assay controls
(Category 3) was voted to be expected in all or most EV-
FC manuscripts by >80% of the WG members, with the
exceptions of isotype (Component 3.4) and detergent
controls (Component 3.8), which were 77% and 74%,
respectively. The poll showed varied expectations for
reporting of instrument data acquisition and calibration
components (Category 4). The reporting of trigger
channel(s) and threshold(s), and flow rate/volumetric
quantification was expected to be reported in all or most
EV-FC manuscripts by ≧88%, while fluorescence calibra-
tion and scatter calibration were voted for in all or most
EV-FC manuscripts by 55% and 37%, respectively. The
reporting of EV characterization (Category 5) in terms of
diameter, refractive index and epitope number using FC
was the least expected information to be required in all or
most EV-FC manuscripts, voted for by ≦20%. The poll
showed that the expectation for reporting of FC data
(Category 6) components in all or most EV-FC manu-
scripts was varied, with EV concentration reporting unan-
imously expected, the completion of the MIFlowCyt
checklist (85%), and the calibration of detection channel
range alongwith reporting EV brightness expected in all or
most manuscripts by 41% of the participants. Finally, the
sharing of FC data (Category 7) was expected to be
reported by 88% of the WG.
In summary, themajority (>50%) ofWGauthors would
expect details pertaining to 19 of 25 framework compo-
nents to be conducted/reported inmanuscripts using single
EV-FC, with >75% consensus on 17 of 25 of the framework
components. The MIFlowCyt-EV components that the
majority of WG authors would currently only expect to
be conducted and reported in select/specialized manu-
script, are those that utilize relatively advanced protocols
and understanding, such as light scatter calibration
(Component 4.4), detection channel calibration
(Component 6.2), EV characterization (Component 5.1,
5.2, 5.3) and reporting of EV brightness (Component 6.4).
While these topics are critical for future standardization,
they are areas that involve the development of new techni-
ques andwheremore tools, teaching and validation studies
may be required before becoming widely utilized. TheWG
authors in this manuscript have outlined a set of compo-
nents that should be broadly considered for all single-FC
experiments, regardless or instrument or assay and feel the
utilization of these components will aid in the development
of more standardized small particle literature.
MIFlowCyt-EV has been developed specifically for the
reporting of single EV-FC experiments and are generally
applicable to other small particles, for example viruses.
A future framework aiming at alternative bulk-EV analy-
sis methods using FC, such as capture-bead assays, may
also be useful. Due to the EV-field being in its infancy, the
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MIFlowCyt-EV is not yet exhaustive and will likely be
adapted and updated in time as the field progresses. The
utilization of this reporting framework will be key in the
development of: (i) standard operating procedures, (ii)
reference materials (iii) and validation studies. The devel-
opment of each of these is required to advance the field
and further improve standardization efforts and will be
supported by this WG. More information on the ISEV-
ISAC-ISTH EV flow cytometry WG updates and
resources can be found at: www.evflowcytometry.org.
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